Table 1

Hydroxy Compounds Generated from PUFA and Recombinant Human COX-2 with ASA or a Selective COX-2 Inhibitor

Hydroxy-containing compounds (ng/incubation)
PUFANSAIDω-2ω-5ω-9
13-HODE9-HODE
C18:2ASA2.9 ± 0.625.2 ± 17.8
C18:2Vehicle alone55.0 ± 18.7243.0 ± 68.6
15R-HETE11R-HETE
C20:4ASA234.0 ± 112.51.4 ± 1.6
C20:4Vehicle alone11.5 ± 8.21.8 ± 1.0
C20:4Selective inhibitor5.5 ± 0.80.9 ± 0.1
18R-HEPE15R-HEPE11R-HEPE
C20:5ASA16.2 ± 3.316.8 ± 5.85.4 ± 3.3
C20:5Vehicle alone7.0 ± 3.317.9 ± 5.240.7 ± 10.3
C20:5Selective inhibitor5.8 ± 2.60.0 ± 0.60.0 ± 0.3
  • Results are the mean ± SEM, n = 3. The selective COX-2 inhibitor NS398 was used at 100 μM. All products were extracted, identified, and quantitated using internal standards and LC/MS/MS. Compounds of interest are shown in bold type.